Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Merimepodib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH1 known ✓ | P20839 | 6/20 | 1.00 |
| ▸ | IMPDH2 | P12268 | 16/20 | 1.00 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Merimepodib SCHEMBL329922 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| Merimepodib SCHEMBL29591763 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| Merimepodib SCHEMBL29376593 | 1.00 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1472876 | 0.95 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1472878 | 0.95 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473611 | 0.95 | IMPDH2 (0.90) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1473608 | 0.95 | IMPDH2 (0.90) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12938851 | 0.93 | IMPDH2 (0.87) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL12368113 | 0.92 | IMPDH2 (0.85) | IMPDH2IMPDH1AAK1 | |
| Merimepodib SCHEMBL28274265 | 0.91 | IMPDH2 (0.83) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922427-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2017223178-A1 | TREATING VIRAL INFECTIONS WITH IMPDH INHIBITORS | TREK THERAPEUTICS, PBC (US) | 2017-12-28 | — | — | WO | claimed |
| US-8153668-B2 | Polymorphic forms of (S)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | claimed |
| US-20090324545-A1 | POLYMORPHIC FORMS OF (S)-1-TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)BENZYL CARBAMATE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | claimed |
| US-7605270-B2 | Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | claimed |
| EP-1891062-A2 | POLYMORPHIC FORMS OF (S)- TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL) PHENYL) UREIDO) BENZYLCARBAMATE | Vertex Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070281980-A1 | Polymorphic forms of (S). -tetrahydrofuran-3-yl-3- (3- (3-methoxy-4- (oxazol-5-yl) pheny1) ureido) benzylcarbamate | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-06 | — | — | US | claimed |
| WO-2006122012-A2 | POLYMORPHIC FORMS OF (S)- TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL) PHENYL) UREIDO) BENZYLCARBAMATE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-16 | — | — | WO | claimed |
| US-20050113321-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | FURMAN PHILIP A (US) | 2005-05-26 | — | — | US | claimed |
| US-20040034206-A1 | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | SCHERING CORPORATION | 2004-02-19 | — | — | US | claimed |
| WO-2004009595-A1 | COMBINATION THERAPY WITH 1,3-DIOXOLANES AND INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORS | TRIANGLE PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | WO | claimed |
| WO-2003101199-A1 | COMBINATION THERAPY FOR RNA VIRUS INFECTIONS INVOLVING RIBAVIRIN AND IMPDH INHIBITORS | SCHERING CORPORATION (US) | 2003-12-11 | — | — | WO | claimed |
| EP-1363704-A2 | DAPD COMBINATION THERAPY WITH INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR | Triangle Pharmaceuticals Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020173491-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | GILEAD SCIENCES, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002068058-A2 | DAPD COMBINATION THERAPY WITH IMDPH INHIBITORS SUCH AS RIBAVIRIN OR MYCOPHENOLIC ACID | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-10882903-B2 | Methods and compositions for treating an alphavirus infection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-01-05 | — | — | US | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-1363704-A2 | DAPD COMBINATION THERAPY WITH INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITOR | Triangle Pharmaceuticals Inc. (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020173491-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | GILEAD SCIENCES, INC. | 2002-11-21 | — | — | US | disclosed |
| WO-2002068058-A2 | DAPD COMBINATION THERAPY WITH IMDPH INHIBITORS SUCH AS RIBAVIRIN OR MYCOPHENOLIC ACID | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281980-A1 | Polymorphic forms of (S). -tetrahydrofuran-3-yl-3- (3- (3-methoxy-4- (oxazol-5-yl) pheny1) ureido) benzylcarbamate | UGT1A1, UGT1A3, UBE2V1 | IMPDH1 411/4885IMPDH2 825/4885AAK1 1595/4885 |
| US-20050113321-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2, AMPD1 | IMPDH1 1/4885IMPDH2 2/4885AAK1 1462/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | IMPDH1 2479/4885IMPDH2 2612/4885AAK1 4305/4885 |
| US-20040034206-A1 | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | IFNAR1, EIF2AK2, IMPDH1 | IMPDH1 3/4885IMPDH2 4/4885AAK1 4332/4885 |
| US-20020173491-A1 | DAPD combination therapy with inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2, AMPD1 | IMPDH1 1/4885IMPDH2 2/4885AAK1 1162/4885 |
| US-20090324545-A1 | POLYMORPHIC FORMS OF (S)-1-TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)BENZYL CARBAMATE | UGT1A3, CYP3A43, UGT1A1 | IMPDH1 184/4885IMPDH2 497/4885AAK1 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.